Solventum (NYSE:SOLV – Get Free Report) released its quarterly earnings results on Tuesday. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.35 by $0.13, FiscalAI reports. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The company had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum updated its FY 2026 guidance to 6.600-6.600 EPS.
Solventum Trading Up 2.4%
NYSE SOLV traded up $1.65 during trading on Tuesday, hitting $69.09. The stock had a trading volume of 1,942,876 shares, compared to its average volume of 1,217,466. Solventum has a one year low of $62.38 and a one year high of $88.20. The stock has a 50 day simple moving average of $67.99 and a 200 day simple moving average of $74.53. The stock has a market capitalization of $11.98 billion, a price-to-earnings ratio of 7.79, a P/E/G ratio of 1.09 and a beta of 0.59. The company has a debt-to-equity ratio of 1.00, a quick ratio of 0.89 and a current ratio of 1.23.
Analyst Ratings Changes
Several research firms have recently issued reports on SOLV. Rothschild & Co Redburn assumed coverage on Solventum in a research note on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price objective for the company. KeyCorp cut their target price on Solventum from $99.00 to $92.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Finally, Mizuho set a $100.00 price objective on shares of Solventum and gave the stock an “outperform” rating in a research note on Tuesday, January 20th. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $89.45.
Insider Activity at Solventum
In other Solventum news, Director Amy Mcbride Wendell bought 1,475 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the completion of the purchase, the director owned 5,039 shares in the company, valued at $342,803.17. This represents a 41.39% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 0.24% of the company’s stock.
Hedge Funds Weigh In On Solventum
A number of large investors have recently bought and sold shares of the business. Boston Partners grew its position in Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after acquiring an additional 959,543 shares during the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Solventum during the third quarter worth $42,393,000. Raymond James Financial Inc. lifted its position in shares of Solventum by 116.5% during the third quarter. Raymond James Financial Inc. now owns 702,411 shares of the company’s stock worth $51,276,000 after purchasing an additional 378,024 shares during the last quarter. Zimmer Partners LP purchased a new stake in shares of Solventum during the third quarter valued at $20,075,000. Finally, AQR Capital Management LLC boosted its stake in shares of Solventum by 82.0% during the fourth quarter. AQR Capital Management LLC now owns 469,288 shares of the company’s stock valued at $37,186,000 after purchasing an additional 211,440 shares during the period.
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.
Further Reading
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
